COMMUNIQUÉS West-GlobeNewswire

Jushi Holdings Inc. Reports Second Quarter 2024 Financial Results
07/08/2024
Margin Growth with Gross Profit and Gross Margin Reaching $32.6 Million and 50.4% , Respectively Net Loss of $1.9 Million , Compared to $14.0 Million in Q2 2023 Grew Adjusted EBITDA and Adjusted EBITDA Margin to $14.5 [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
07/08/2024
Reported dose-dependent antitumor clinical activity in patients with relapsed/refractory triple-negative breast cancer from the Phase 1 trial of LYL797, a ROR1-targeted Chimeric Antigen Receptor (CAR) T‑cell product [...]
Telesis Bio Reports Second Quarter and First Half 2024 Financial Results
07/08/2024
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid [...]
LifeMD Reports Second Quarter 2024 Results
07/08/2024
Revenue increased 41% year-over-year to $50.7 million with telehealth revenue up 67% Telehealth achieved standalone profitability one quarter ahead of guidance, with adjusted EBITDA of $820,000 Weight management [...]
Cartesian Therapeutics Announces New Employment Inducement Grants
07/08/2024
GAITHERSBURG, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune [...]
ICU Medical Announces Second Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance
07/08/2024
SAN CLEMENTE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the [...]
Silk Road Medical Reports Second Quarter 2024 Financial Results
07/08/2024
SUNNYVALE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three [...]
ClearPoint Neuro Reports Second Quarter 2024 Results
07/08/2024
Second Quarter Revenue Growth +32%; Record Revenue Achieved SOLANA BEACH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company [...]
Maravai LifeSciences Reports Second Quarter 2024 Financial Results
07/08/2024
Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of [...]
Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
07/08/2024
Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete SVR12 Results Expected 4Q’24 Bemnifosbuvir and Ruzasvir HCV Data Presented at EASL: Support Best-in-Class Potential with High Antiviral [...]
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
07/08/2024
Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced cough severity in IPF patients treated with bexotegrast Positive long-term data from INTEGRIS- [...]
PacBio Announces Second Quarter 2024 Financial Results
07/08/2024
MENLO PARK, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2024. Second quarter results: Revenue of $36.0 million compared with $47.6 [...]
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
07/08/2024
TARRYTOWN, N.Y., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) announces the following September 2024 investor events: Investor Conference Presentations • Morgan Stanley 22 nd Annual [...]
Elutia Announces Second Quarter 2024 Results
07/08/2024
Launch Production of EluPro® Underway, Commercial Team Expansion Continues, Financial Position Solidified SILVER SPRING, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a [...]
Generation Bio Reports Second Quarter 2024 Financial Results
07/08/2024
Cash balance of $217 million still expected to fund operations into 2H 2027 CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), a biotechnology company innovating genetic medicines [...]
Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
07/08/2024
Outcome of pre-planned Reliance II interim analysis anticipated by YE 2024 Enrollment in Phase 3 Reliance II study expected to be completed by YE 2024 Preparations on track to initiate Phase 1 study for REL-P11 for [...]
Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07/08/2024
-Recently Held Positive Pre-BLA Meeting with FDA with Aim to Accelerate Approval Pathway of Deramiocel for the Treatment of Duchenne Muscular Dystrophy- -Phase 3, HOPE-3 Trial of Deramiocel in DMD Fully Enrolled; On [...]
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
07/08/2024
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
07/08/2024
Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation in Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024 Patient Screening for Minimal Residual Disease (MRD) and Enrollment Proceeding [...]

Pages